Pharmacogenomics and epilepsy: The road ahead

Pharmacogenomics

Volumn 12, Issue 10, 2011, Pages 1429-1447

  Cavalleri, Gianpiero L ^a   McCormack, Mark ^a   Alhusaini, Saud ^a   Chaila, Elijah ^b   Delanty, Norman ^a,b  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b BEAUMONT HOSPITAL   (Ireland)

Author keywords

adverse drug reactions; epilepsy; GWAS; pharmacogenetics; pharmacogenomics; refractory epilepsy; whole genome sequencing

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; CYTOCHROME P450 2C9; DIAZEPAM; ESLICARBAZEPINE; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; FOSPHENYTOIN SODIUM; GABAPENTIN; HARKOSERIDE; HLA A ANTIGEN; HLA B ANTIGEN; LAMOTRIGINE; MEPHENYTOIN; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; RUFINAMIDE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ABCC2 GENE; ABCG2 GENE; ADD ON THERAPY; ANOREXIA; ATAXIA; BEHAVIOR DISORDER; BLOOD DYSCRASIA; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL NERVOUS SYSTEM INFECTION; CYP2C9 GENE; DISEASE CONTROL; DIZZINESS; DRESS SYNDROME; DROWSINESS; DRUG CHOICE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG METABOLISM; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EPILEPSY; FOCAL EPILEPSY; GENE; GENE SEQUENCE; GENERALIZED EPILEPSY; GENETIC ASSOCIATION; GENOTYPE; GINGIVA HYPERTROPHY; HEREDITY; HIRSUTISM; HUMAN; HYPERSENSITIVITY; HYPONATREMIA; INSOMNIA; LANGUAGE DISABILITY; LENNOX GASTAUT SYNDROME; LIVER FAILURE; MACULOPAPULAR RASH; MENTAL DISEASE; MONOTHERAPY; NEPHROLITHIASIS; OSTEOMALACIA; OSTEOPOROSIS; PHARMACOGENETICS; PHARMACOGENOMICS; PHENOTYPE; REVIEW; SEIZURE; SEVERE MYOCLONIC EPILEPSY IN INFANCY; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN TOXICITY; SOMNOLENCE; STEVENS JOHNSON SYNDROME; TREATMENT RESPONSE; VISUAL DISORDER; WEIGHT GAIN; WEIGHT REDUCTION;

ALLELES; ANTICONVULSANTS; BIOMARKERS, PHARMACOLOGICAL; EPILEPSY; GENOME-WIDE ASSOCIATION STUDY; HUMANS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 80054890105     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.85     Document Type: Review

References (136)

1. Heaney DC, Macdonald BK, Everitt A et al. Socioeconomic variation in incidence of epilepsy: prospective community based study in south east England. BMJ 325(7371), 1013-1016 (2002). (Pubitemid 35305153)
2. Sander JW. The epidemiology of epilepsy revisited. Curr. Opin. Neurol. 16(2), 165-170 (2003). (Pubitemid 36521202)
3. Banerjee PN, Filippi D, Allen Hauser W. The descriptive epidemiology of epilepsy-a review. Epilepsy Res. 85(1), 31-45 (2009).
4. Brodie MJ, French JA. Management of epilepsy in adolescents and adults. Lancet 356(9226), 323-329 (2000). (Pubitemid 30459597)
5. Neal EG, Chaffe H, Schwartz RH et al. The ketogenic diet for the treatment of childhood epilepsy. a randomised controlled trial. Lancet Neurol. 7(6), 500-506 (2008).
6. Dunlea O, Doherty CP, Farrell M et al. The Irish epilepsy surgery experience. Long-term follow-up. Seizure 19(4), 247-252 (2010).
7. Vonck K, De Herdt V, Boon P. Vagal nerve stimulation-a 15-year survey of an established treatment modality in epilepsy surgery. Adv. Tech. Stand Neurosurg. 34, 111-146 (2009).
8. Ardesch JJ, Buschman HP, Wagener-Schimmel LJ, Van Der Aa HE, Hageman G. Vagus nerve stimulation for medically refractory epilepsy: a long-term follow-up study. Seizure 16(7), 579-585 (2007). (Pubitemid 47307249)
9. Cavalleri GL, Lynch JM, Depondt C et al. Failure to replicate previously reported genetic associations with sporadic temporal lobe epilepsy. where to from here? Brain 128(Pt 8), 1832-1840 (2005). (Pubitemid 41373654)
10. Tan NC, Mulley JC, Berkovic SF. Genetic association studies in epilepsy: 'the truth is out there'. Epilepsia 45(11), 1429-1442 (2004). (Pubitemid 39470047)
11. Hindorff LA, Sethupathy P, Junkins HA et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc. Natl Acad. Sci. USA 106(23), 9362-9367 (2009).
12. Manolio TA, Collins FS, Cox NJ et al. Finding the missing heritability of complex diseases. Nature 461(7265), 747-753 (2009).
13. Dickson SP, Wang K, Krantz I, Hakonarson H, Goldstein DB. Rare variants create synthetic genome-wide associations. PLoS Biol. 8(1), e1000294 (2010).
14. Panagiotou OA, Evangelou E, Ioannidis JP. Genome-wide significant associations for variants with minor allele frequency of 5% or less-an overview: a HuGE review. Am. J. Epidemiol. 172(8), 869-889 (2010).
15. Anderson CA, Soranzo N, Zeggini E, Barrett JC. Synthetic associations are unlikely to account for many common disease genome-wide association signals. PLoS Biol. 9(1), e1000580 (2011).
16. Wray NR, Purcell SM, Visscher PM. Synthetic associations created by rare variants do not explain most GWAS results. PLoS Biol. 9(1), e1000579 (2011).
17. Lazarowski A, Czornyj L, Lubienieki F, Girardi E, Vazquez S, D'giano C. ABC transporters during epilepsy and mechanisms underlying multidrug resistance in refractory epilepsy. Epilepsia 48(Suppl. 5), 140-149 (2007). (Pubitemid 47512215)
18. Siddiqui A, Kerb R, Weale ME et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N. Engl. J. Med. 348(15), 1442-1448 (2003). (Pubitemid 36407173)
19. Kasperaviciute D, Sisodiya SM. Epilepsy pharmacogenetics. Pharmacogenomics 10(5), 817-836 (2009).
20. Bournissen FG, Moretti ME, Juurlink DN, Koren G, Walker M, Finkelstein Y. Polymorphism of the MDR1/ABCB1 C3435T drug-transporter and resistance to anticonvulsant drugs: a meta-analysis. Epilepsia 50(4), 898-903 (2009).
21. Haerian BS, Lim KS, Tan CT, Raymond AA, Mohamed Z. Association of ABCB1 gene polymorphisms and their haplotypes with response to antiepileptic drugs: a systematic review and meta-analysis. Pharmacogenomics 12(5), 713-725 (2011).
22. Hung CC, Tai JJ, Lin CJ, Lee MJ, Liou HH. Complex haplotypic effects of the ABCB1 gene on epilepsy treatment response. Pharmacogenomics 6(4), 411-417 (2005). (Pubitemid 40916364)
23. Hung CC, Chen CC, Lin CJ, Liou HH. Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenet. Genomics 18(5), 390-402 (2008).
24. Ufer M, Mosyagin I, Muhle H et al. Non-response to antiepileptic pharmacotherapy is associated with the ABCC2-24C T polymorphism in young and adult patients with epilepsy. Pharmacogenet. Genomics 19(5), 353-362 (2009).
25. Kim DW, Lee SK, Chu K et al. Lack of association between ABCB1, ABCG2, and ABCC2 genetic polymorphisms and multidrug resistance in partial epilepsy. Epilepsy Res. 84(1), 86-90 (2009).
26. Kwan P, Sperling MR. Refractory seizures: try additional antiepileptic drugs (after two have failed) or go directly to early surgery evaluation? Epilepsia 50(Suppl. 8), 57-62 (2009).
27. Arts WF, Geerts AT, Brouwer OF, Boudewyn Peters AC, Stroink H, Van Donselaar CA. The early prognosis of epilepsy in childhood: the prediction of a poor outcome. The Dutch study of epilepsy in childhood. Epilepsia 40(6), 726-734 (1999). (Pubitemid 29260711)
28. Dlugos DJ, Sammel MD, Strom BL, Farrar JT. Response to first drug trial predicts outcome in childhood temporal lobe epilepsy. Neurology 57(12), 2259-2264 (2001). (Pubitemid 34016461)
29. Kwan P, Brodie MJ. Drug treatment of epilepsy: when does it fail and how to optimize its use? CNS Spectr. 9(2), 110-119 (2004). (Pubitemid 38405563)
30. Berg AT, Shinnar S, Levy SR, Testa FM, Smith-Rapaport S, Beckerman B. Early development of intractable epilepsy in children: a prospective study. Neurology 56(11), 1445-1452 (2001). (Pubitemid 32532255)
31. Kwan P, Arzimanoglou A, Berg AT et al. Definition of drug resistant epilepsy. consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies. Epilepsia 51(6), 1069-1077 (2010).
32. Luna-Tortos C, Rambeck B, Jurgens UH, Loscher W. The antiepileptic drug topiramate is a substrate for human P-glycoprotein but not multidrug resistance proteins. Pharm. Res. 26(11), 2464-2470 (2009).
33. Baltes S, Gastens AM, Fedrowitz M, Potschka H, Kaever V, Loscher W. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology 52(2), 333-346 (2007). (Pubitemid 46123353)
34. Luna-Tortos C, Fedrowitz M, Loscher W. Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology 55(8), 1364-1375 (2008).
35. Cucullo L, Hossain M, Rapp E, Manders T, Marchi N, Janigro D. Development of a humanized in vitro blood-brain barrier model to screen for brain penetration of antiepileptic drugs. Epilepsia 48(3), 505-516 (2007). (Pubitemid 46365189)
36. Sanchez MB, Herranz JL, Leno C et al. Genetic factors associated with drug-resistance of epilepsy. relevance of stratification by patient age and aetiology of epilepsy. Seizure 19(2), 93-101 (2010).
37. Petrovski S, Szoeke CE, Sheffield LJ, D'souza W, Huggins RM, O'Brien TJ. Multi-SNP pharmacogenomic classifier is superior to single-SNP models for predicting drug outcome in complex diseases. Pharmacogenet. Genomics 19(2), 147-152 (2009).
38. Claes L, Del-Favero J, Ceulemans B, Lagae L, Van Broeckhoven C, De Jonghe P. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am. J. Hum. Genet. 68(6), 1327-1332 (2001). (Pubitemid 32510608)
39. Depienne C, Trouillard O, Saint-Martin C et al. Spectrum of SCN1A gene mutations associated with Dravet syndrome. analysis of 333 patients. J. Med. Genet. 46(3), 183-191 (2009).
40. Chiron C, Dulac O. The pharmacologic treatment of Dravet syndrome. Epilepsia 52 Suppl 2, 72-75 (2011).
41. Yu FH, Mantegazza M, Westenbroek RE et al. Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. Nat. Neurosci. 9(9), 1142-1149 (2006). (Pubitemid 44306307)
42. Martin MS, Dutt K, Papale LA et al. Altered function of the SCN1A voltage-gated sodium channel leads to gamma-aminobutyric acid-ergic (GABAergic) interneuron abnormalities. J. Biol. Chem. 285(13), 9823-9834 (2010).
43. Korff C, Laux L, Kelley K, Goldstein J, Koh S, Nordli D Jr. Dravet syndrome (severe myoclonic epilepsy in infancy): a retrospective study of 16 patients. J Child Neurol. 22(2), 185-194 (2007). (Pubitemid 46860417)
44. Delgado-Escueta AV, Bourgeois BF. Debate: does genetic information in humans help us treat patients? PRO-genetic information in humans helps us treat patients. CON-genetic information does not help at all. Epilepsia 49(Suppl. 9), 13-24 (2008).
45. Scheffer IE, Zhang YH, Jansen FE, Dibbens L. Dravet syndrome or genetic (generalized) epilepsy with febrile seizures plus? Brain Dev. 31(5), 394-400 (2009).
46. Nicolson A, Lewis SA, Smith DF. A prospective analysis of the outcome of levetiracetam in clinical practice. Neurology 63(3), 568-570 (2004). (Pubitemid 39031397)
47. Abe T, Seo T, Ishitsu T, Nakagawa T, Hori M, Nakagawa K. Association between SCN1A polymorphism and carbamazepine-resistant epilepsy. Br. J. Clin. Pharmacol. 66(2), 304-307 (2008).
48. Lynch JM, Tate SK, Kinirons P et al. No major role of common SV2A variation for predisposition or levetiracetam response in epilepsy. Epilepsy Res. 83(1), 44-51 (2009).
49. Grover S, Talwar P, Gourie-Devi M et al. Genetic polymorphisms in sex hormone metabolizing genes and drug response in women with epilepsy. Pharmacogenomics 11(11), 1525-1534 (2010).
50. Kupfer A, Preisig R. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur. J. Clin. Pharmacol. 26(6), 753-759 (1984). (Pubitemid 14074652)
51. Kerr BM, Thummel KE, Wurden CJ et al. Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem. Pharmacol. 47(11), 1969-1979 (1994).
52. Van Der Weide J, Steijns LS, Van Weelden MJ, De Haan K. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics 11(4), 287-291 (2001). (Pubitemid 32537401)
53. Takanashi K, Tainaka H, Kobayashi K, Yasumori T, Hosakawa M, Chiba K. CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics 10(2), 95-104 (2000). (Pubitemid 30193071)
54. Rettie AE, Haining RL, Bajpai M, Levy RH. A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin. Epilepsy Res. 35(3), 253-255 (1999). (Pubitemid 29298118)
55. Aynacioglu AS, Brockmoller J, Bauer S et al. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br. J. Clin. Pharmacol. 48(3), 409-415 (1999). (Pubitemid 29417726)
56. Hung CC, Lin CJ, Chen CC, Chang CJ, Liou HH. Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms. Ther. Drug Monit. 26(5), 534-540 (2004).
57. Allabi AC, Gala JL, Horsmans Y. CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Pharmacogenet. Genomics 15(11), 779-786 (2005). (Pubitemid 41531727)
58. Rosemary J, Surendiran A, Rajan S, Shashindran CH, Adithan C. Influence of the CYP2C9 and CYP2C19 polymorphisms on phenytoin hydroxylation in healthy individuals from south India. Indian J. Med. Res. 123(5), 665-670 (2006). (Pubitemid 44083210)
59. Argikar UA, Cloyd JC, Birnbaum AK et al. Paradoxical urinary phenytoin metabolite (S)/(R) ratios in CYP2C19*1/*2 patients. Epilepsy Res. 71(1), 54-63 (2006). (Pubitemid 44233199)
60. Lee SY, Lee ST, Kim JW. Contributions of CYP2C9/CYP2C19 genotypes and drug interaction to the phenytoin treatment in the Korean epileptic patients in the clinical setting. J. Biochem. Mol. Biol. 40(3), 448-452 (2007).
61. Tate SK, Depondt C, Sisodiya SM et al. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc. Natl Acad. Sci. USA 102(15), 5507-5512 (2005). (Pubitemid 40530288)
62. Chaudhry AS, Urban TJ, Lamba JK et al. CYP2C9*1B promoter polymorphisms, in linkage with CYP2C19*2, affect phenytoin autoinduction of clearance and maintenance dose. J. Pharmacol. Exp. Ther. 332(2), 599-611 (2010).
63. Pelkonen O, Myllynen P, Taavitsainen P et al. Carbamazepine. A 'blind' assessment of CVP-associated metabolism and interactions in human liver-derived in vitro systems. Xenobiotica 31(6), 321-343 (2001). (Pubitemid 32679311)
64. Nakajima Y, Saito Y, Shiseki K et al. Haplotype structures of EPHX1 and their effects on the metabolism of carbamazepine-10,11-epoxide in Japanese epileptic patients. Eur. J. Clin. Pharmacol. 61(1), 25-34 (2005). (Pubitemid 40558276)
65. Makmor-Bakry M, Sills GJ, Hitiris N, Butler E, Wilson EA, Brodie MJ. Genetic variants in microsomal epoxide hydrolase influence carbamazepine dosing. Clin. Neuropharmacol. 32(4), 205-212 (2009).
66. Heinzen EL, Yoon W, Tate SK et al. Nova2 interacts with a cis-acting polymorphism to influence the proportions of drug-responsive splice variants of SCN1A. Am. J. Hum. Genet. 80(5), 876-883 (2007). (Pubitemid 46668456)
67. Tate SK, Singh R, Hung CC et al. A common polymorphism in the SCN1A gene associates with phenytoin serum levels at maintenance dose. Pharmacogenet. Genomics 16(10), 721-726 (2006). (Pubitemid 44454866)
68. Zimprich F, Stogmann E, Bonelli S et al. A functional polymorphism in the SCN1A gene is not associated with carbamazepine dosages in Austrian patients with epilepsy. Epilepsia 49(6), 1108-1109 (2008). (Pubitemid 351794005)
69. Kim WJ, Lee JH, Yi J et al. A nonsynonymous variation in MRP2/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy. Pharmacogenet. Genomics 20(4), 249-256 (2010).
70. Jose L, Binila C, Chandy SJ, Mathews JE, Mathews KP. Acenocoumarol and phenytoin toxicity in the presence of CYP2C9 mutation. J. Assoc. Physicians India 56, 250-252 (2008).
71. Ramasamy K, Narayan SK, Chanolean S, Chandrasekaran A. Severe phenytoin toxicity in a CYP2C9*3*3 homozygous mutant from India. Neurol. India 55(4), 408-409 (2007). (Pubitemid 350179258)
72. Brandolese R, Scordo MG, Spina E, Gusella M, Padrini R. Severe phenytoin intoxication in a subject homozygous for CYP2C9*3. Clin. Pharmacol. Ther. 70(4), 391-394 (2001). (Pubitemid 33022480)
73. Citerio G, Nobili A, Airoldi L, Pastorelli R, Patruno A. Severe intoxication after phenytoin infusion: a preventable pharmacogenetic adverse reaction. Neurology 60(8), 1395-1396 (2003). (Pubitemid 36461010)
74. Ninomiya H, Mamiya K, Matsuo S, Ieiri I, Higuchi S, Tashiro N. Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication. Ther. Drug Monit. 22(2), 230-232 (2000). (Pubitemid 30196831)
75. Mccluggage LK, Voils SA, Bullock MR. Phenytoin toxicity due to genetic polymorphism. Neurocrit. Care 10(2), 222-224 (2009).
76. Kesavan R, Narayan SK, Adithan C. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients. Eur. J. Clin. Pharmacol. 66(7), 689-696 (2010).
77. Depondt C, Godard P, Espel RS, Da Cruz AL, Lienard P, Pandolfo M. A candidate gene study of antiepileptic drug tolerability and efficacy identifies an association of CYP2C9 variants with phenytoin toxicity. Eur. J. Neurol. (2011).
78. Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. BMJ 314(7075), 180-181 (1997). (Pubitemid 27037871)
79. Kalviainen R, Nousiainen I, Mantyjarvi M et al. Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects. Neurology 53(5), 922-926 (1999). (Pubitemid 29442104)
80. Tolman JA, Faulkner MA. Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval. Expert Opin. Pharmacother. 10(18), 3077-3089 (2009).
81. Paul SR, Krauss GL, Miller NR, Medura MT, Miller TA, Johnson MA. Visual function is stable in patients who continue long-term vigabatrin therapy: implications for clinical decision making. Epilepsia 42(4), 525-530 (2001). (Pubitemid 32322198)
82. Clayton LM, Devile M, Punte T et al. Retinal nerve fiber layer thickness in Vigabatrin-exposed patients. Ann. Neurol. (2011).
83. Conway M, Cubbidge RP, Hosking SL. Visual field severity indices demonstrate dose-dependent visual loss from vigabatrin therapy. Epilepsia 49(1), 108-116 (2008).
84. Wild JM, Chiron C, Ahn H et al. Visual field loss in patients with refractory partial epilepsy treated with vigabatrin. final results from an open-label, observational, multicentre study. CNS Drugs 23(11), 965-982 (2009).
85. Hardus P, Verduin WM, Engelsman M et al. Visual field loss associated with vigabatrin. quantification and relation to dosage. Epilepsia 42(2), 262-267 (2001). (Pubitemid 32204810)
86. Kinirons P, Cavalleri GL, Singh R et al. A pharmacogenetic exploration of vigabatrin-induced visual field constriction. Epilepsy Res. 70(2-3), 144-152 (2006). (Pubitemid 44189176)
87. Arif H, Buchsbaum R, Weintraub D et al. Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology 68(20), 1701-1709 (2007). (Pubitemid 46763258)
88. Syn WK, Naisbitt DJ, Holt AP, Pirmohamed M, Mutimer DJ. Carbamazepine-induced acute liver failure as part of the DRESS syndrome. Int. J. Clin. Pract. 59(8), 988-991 (2005).
89. Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet. J. Rare Dis. 5, 39 (2010).
90. Chung WH, Hung SI, Hong HS et al. Medical genetics. a marker for Stevens-Johnson syndrome. Nature 428(6982), 486 (2004).
91. Ding WY, Lee CK, Choon SE. Cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia. Int. J. Dermatol. 49(7), 834-841 (2010).
92. Locharernkul C, Loplumlert J, Limotai C et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia 49(12), 2087-2091 (2008).
93. Lonjou C, Thomas L, Borot N et al. A marker for Stevens-Johnson syndrome-ethnicity matters. Pharmacogenomics J. 6(4), 265-268 (2006).
94. Lonjou C, Borot N, Sekula P et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet. Genomics 18(2), 99-107 (2008).
95. Alfirevic A, Jorgensen AL, Williamson PR, Chadwick DW, Park BK, Pirmohamed M. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 7(6), 813-818 (2006). (Pubitemid 44446732)
96. Hung SI, Chung WH, Liu ZS et al. Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics 11(3), 349-356 (2010).
97. Man CB, Kwan P, Baum L et al. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 48(5), 1015-1018 (2007). (Pubitemid 46763406)
98. An DM, Wu XT, Hu FY, Yan B, Stefan H, Zhou D. Association study of lamotrigine-induced cutaneous adverse reactions and HLA-B*1502 in a Han Chinese population. Epilepsy Res. 92(2-3), 226-230 (2010).
99. Chen YC, Chu CY, Hsiao CH. Oxcarbazepine-induced Stevens-Johnson syndrome in a patient with HLA-B*1502 genotype. J. Eur. Acad. Dermatol. Venereol. 23(6), 702-703 (2009).
100. Hu FY, Wu XT, An DM, Yan B, Stefan H, Zhou D. Pilot association study of oxcarbazepine-induced mild cutaneous adverse reactions with HLA-B*1502 allele in Chinese Han population. Seizure 20(2), 160-162 (2011).
101. Ozeki T, Mushiroda T, Yowang A et al. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum. Mol. Genet. 20(5), 1034-1041 (2011).
102. Mccormack M, Alfirevic A, Bourgeois S et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N. Engl. J. Med. 364(12), 1134-1143 (2011).
103. Chen P, Lin JJ, Lu CS et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N. Engl. J. Med. 364(12), 1126-1133 (2011).
104. Tassaneeyakul W, Jantararoungtong T, Chen P et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet. Genomics 19(9), 704-709 (2009).
105. Hung SI, Chung WH, Liou LB et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl Acad. Sci. USA 102(11), 4134-4139 (2005).
106. Mallal S, Nolan D, Witt C et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359(9308), 727-732 (2002). (Pubitemid 34215071)
107. Marini C, Scheffer IE, Nabbout R et al. SCN1A duplications and deletions detected in Dravet syndrome. implications for molecular diagnosis. Epilepsia 50(7), 1670-1678 (2009).
108. Herini ES, Gunadi, Harahap IS et al. Generalized epilepsy with febrile seizures plus (GEFS+) spectrum. Clinical manifestations and SCN1A mutations in Indonesian patients. Epilepsy Res. 90(1-2), 132-139 (2010).
109. Marini C, Mei D, Temudo T et al. Idiopathic epilepsies with seizures precipitated by fever and SCN1A abnormalities. Epilepsia 48(9), 1678-1685 (2007). (Pubitemid 47352865)
110. Sisodiya SM, Mefford HC. Genetic contribution to common epilepsies. Curr. Opin. Neurol. 24(2), 140-145 (2011).
111. Helbig I, Mefford HC, Sharp AJ et al. 15q13.3 microdeletions increase risk of idiopathic generalized epilepsy. Nat. Genet. 41(2), 160-162 (2009).
112. De Kovel CG, Trucks H, Helbig I et al. Recurrent microdeletions at 15q11.2 and 16p13.11 predispose to idiopathic generalized epilepsies. Brain 133(Pt 1), 23-32 (2010).
113. Heinzen EL, Radtke RA, Urban TJ et al. Rare deletions at 16p13.11 predispose to a diverse spectrum of sporadic epilepsy syndromes. Am. J. Hum. Genet. 86(5), 707-718 (2010).
114. Catarino CB, Kasperaviciute D, Thom M et al. Genomic microdeletions associated with epilepsy. Not a contraindication to resective surgery. Epilepsia 52(8), 1388-1392 (2011).
115. Pal DK, Pong AW, Chung WK. Genetic evaluation and counseling for epilepsy. Nat. Rev. Neurol. 6(8), 445-453 (2010).
116. Lango Allen H, Estrada K, Lettre G et al. Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature 467(7317), 832-838 (2010).
117. Speliotes EK, Willer CJ, Berndt SI et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat. Genet. 42(11), 937-948 (2010).
118. Berg AT, Kelly MM. Defining intractability: comparisons among published definitions. Epilepsia 47(2), 431-436 (2006).
119. Kasperaviciute D, Catarino CB, Heinzen EL et al. Common genetic variation and susceptibility to partial epilepsies. a genome-wide association study. Brain 133(Pt 7), 2136-2147 (2010).
120. Tassaneeyakul W, Tiamkao S, Jantararoungtong T et al. Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population. Epilepsia 51(5), 926-930 (2010).
121. Kaniwa N, Saito Y, Aihara M et al. HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia 51(12), 2461-2465 (2010).
122. Ikeda H, Takahashi Y, Yamazaki E et al. HLA class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions. Epilepsia 51(2), 297-300 (2010).
123. Shi YW, Min FL, Liu XR et al. HLA-B alleles and lamotrigine-induced cutaneous adverse drug reactions in the Han Chinese population. Basic Clin. Pharmacol. Toxicol. 109(1), 42-46 (2011).
124. Kazeem GR, Cox C, Aponte J et al. High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients. Pharmacogenet. Genomics 19(9), 661-665 (2009).
125. Manna I, Gambardella A, Bianchi A et al. A functional polymorphism in the SCN1A gene does not influence antiepileptic drug responsiveness in Italian patients with focal epilepsy. Epilepsia 52(5), e40-e44 (2011).
126. Grover S, Bala K, Sharma S et al. Absence of a general association between ABCB1 genetic variants and response to antiepileptic drugs in epilepsy patients. Biochimie 92(9), 1207-1212 (2010).
127. Grover S, Gourie-Devi M, Baghel R et al. Genetic profile of patients with epilepsy on first-line antiepileptic drugs and potential directions for personalized treatment. Pharmacogenomics 11(7), 927-941 (2010).
128. Simon C, Stieger B, Kullak-Ublick GA et al. Intestinal expression of cytochrome P450 enzymes and ABC transporters and carbamazepine and phenytoin disposition. Acta Neurol. Scand. 115(4), 232-242 (2007). (Pubitemid 46449584)
129. Gulcebi MI, Ozkaynakci A, Goren MZ, Aker RG, Ozkara C, Onat FY. The relationship between UGT1A4 polymorphism and serum concentration of lamotrigine in patients with epilepsy. Epilepsy Res. (2011).
130. Blanca Sanchez M, Herranz JL, Leno C et al. UGT2B7-161C T polymorphism is associated with lamotrigine concentration-to-dose ratio in a multivariate study. Ther. Drug Monit. 32(2), 177-184 (2010).
131. Mamiya K, Hadama A, Yukawa E et al. CYP2C19 polymorphism effect on phenobarbitone. Pharmacokinetics in Japanese patients with epilepsy. analysis by population pharmacokinetics. Eur. J. Clin. Pharmacol. 55(11-12), 821-825 (2000).
132. Goto S, Seo T, Murata T et al. Population estimation of the effects of cytochrome P450 2C9 and 2C19 polymorphisms on phenobarbital clearance in Japanese. Ther. Drug Monit. 29(1), 118-121 (2007). (Pubitemid 46279885)
133. Kerb R, Aynacioglu AS, Brockmoller J et al. The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenomics J. 1(3), 204-210 (2001).
134. Wang Y, Gao L, Liu YP, Huang NN, Xu SJ, Ma DJ. Effect of UGTIA6 A541G genetic polymorphism on the metabolism of valproic acid in Han epileptic children from Henan. Zhongguo Dang Dai Er Ke Za Zhi 12(6), 429-432 (2010).
135. Okada Y, Seo T, Ishitsu T et al. Population estimation regarding the effects of cytochrome P450 2C19 and 3A5 polymorphisms on zonisamide clearance. Ther. Drug Monit. 30(4), 540-543 (2008).
136. Sistonen J, Fuselli S, Palo JU, Chauhan N, Padh H, Sajantila A. Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales. Pharmacogenet. Genomics 19(2), 170-179 (2009).